Preclinical studies of mesenchymal stem cells transplantation in amyotrophic lateral sclerosis: a systemic review and metaanalysis

Potential of Cellular Therapy for ALS: Current Strategies and Future Prospects

“…Nowadays, MSCs are considered a promising tool for ALS cellular therapy due to the following reasons: 1) MSCs can be effectively and safely obtained from somatic tissues and can be easily expanded in vitro culture systems; 2) MSCs can migrate to injury tissue sites, a property called “homing” that is mediated by chemokines; 3) MSCs can release various biological factors to facilitate nervous tissue maintenance and repair; 4) MSCs may develop neuronal phenotypes under appropriate conditions; 5) MSCs have lower ethical concerns than ESCs or fetal-derived stem cells; 6) autologous MSCs can be safely administered without the risk of immune rejection; and 7) MSCs can secrete exosomes that modulate the microenvironment ( Karussis et al, 2010 ; Baglio et al, 2012 ; Zhou et al, 2021 ).…”

Mesenchymal stem cell secretome and extracellular vesicles for neurodegenerative diseases: Risk-benefit profile and next steps for the market access

“…The safety and efficacy of MSCs undoubtedly emerge, as highlighted by recent systemic reviews and meta-analyses of the literature. For example, regarding the efficacy, transplantation of MSCs significantly improved memory loss and cognitive impairment in AD [ 35 ], rotational behavior and limb function in PD [ 36 ], improved neurobehavior in ALS [ 37 ], ameliorated the symptoms and delayed the progression of MS [ 38 ], promoted the recovery of nerve function and exerted a protective effect on the brain of cerebral AIS rats [ 39 ], and improved sensorimotor functions in SCI [ 40 ].…”